The specialist must record: Current body weight
You can read the full article at The SURPASS-2 trial evaluated the efficacy and safety of tirzepatide, a dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 (GLP-1) receptor agonist, for the treatment of type 2 diabetes
However, it is not a miracle cure for weight loss or an energy boost in those with normal B12 levels
It found that patients with diabetes who were prescribed semaglutide, which is marketed as Wegovy and Ozempic, were about four times more likely to be diagnosed with non-arteritic anterior ischemic optic neuropathy (NAION), an eye condition that is painless but cannot be treated or cured
The dual-agonist question One theoretical question that researchers have not fully addressed is whether tirzepatide's GIP activation creates any additional considerations during breastfeeding
A Phase 1 study of healthy volunteers conducted in Europe has completed enrollment, with a total of 201 subjects enrolled